BioAtla, Inc. (BCAB) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 6 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for BCAB is $5.00, representing a +19.0% upside from the current price of $4.2. Price targets range from a low of $5.00 to a high of $5.00.
